Ryaltris (Olopatadine HCl/Mometasone) Patent Expiration, LOE Window & CMS Spending

Ryaltris (Olopatadine HCl/Mometasone) by Glenmark Specialty Sa: FDA Orange Book core substance LOE 2039-04-08 (last listed 2044-11-21), 0 AB generics, $4.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGlenmark Specialty Sa
FDA Application & PathwayN211746 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2039-04-08
Last Listed Patent or Exclusivity Date2044-11-21
Orange Book Patents (*PED Extensions)17 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$4.3M
2024 Medicare Part D Spend$3.0M
2024 Medicaid Spend$1.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel